Search
Sipavibart
go.drugbank.com/drugs/DB21908ApprovedInvestigationalSipavibart is a recombinant human IgG1 monoclonal antibody that is long-acting. … [A274088] It was later approved in Europe in January 2025 and in Canada in March 2025.
Synonyms: Gamma1 heavy chain Homo sapiens (1-455) [VH (Homo sapiens IGHV3-9*01 (94.9%) -(IGHD) -IGHJ1*01 (90.9%) L123>T (120), CDR-IMGT [8.8.18] (26-33.51-58.97-114)) (1-125) -Homo sapiens IGHG1*03, G1m3, nG1m1Gantenerumab
go.drugbank.com/drugs/DB12034InvestigationalDespite the clear association of Aβ aggregation with AD, treatments aimed at preventing Aβ aggregation or removing pre-existing Aβ plaques have shown little to no clinical benefit thus far and remain controversial … treatments include the related antibodies [aducanumab], which has been granted accelerated FDA approval, along with [bapineuzumab], [crenezumab], [donanemab], [lecanemab], and [solanezumab], which are at
Givosiran
go.drugbank.com/drugs/DB15066ApprovedGivosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. … [L10202] Givosiran represents an important step forward in the treatment of acute hepatic porphyria as it is the first approved pharmacotherapy for the prevention of acute attacks - previous strategies
Fruquintinib
go.drugbank.com/drugs/DB11679ApprovedInvestigationalThe first approach can be exemplified by [bevacizumab], a VEGF-A trap antibody. … Therefore, the advent of fruquintinib, a new generation of VEGFR inhibitors with a high kinome selectivity, demonstrated the feasibility of the small-molecule inhibitor approach.
AT2220
go.drugbank.com/drugs/DB05200InvestigationalIt is a small molecule designed to act as a pharmacological chaperone that specifically binds, stabilizes, and facilitates the proper folding and trafficking of α-glucosidase (GAA). … AT2220 is an experimental, oral therapy for the treatment of Pompe disease and belongs to a class of molecules known as pharmacological chaperones.
Snail, unspecified
go.drugbank.com/drugs/DB14245ApprovedInvestigationalSnail, unspecified is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.
Nabumetone
go.drugbank.com/drugs/DB00461ApprovedNabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID). … [label,A178903] The molecule itself is a pro-drug with its 6-methoxy-2-naphthylacetic acid (6-MNA) metabolite acting as a potent COX inhibitor similar in structure to [naproxen].
Atrasentan
go.drugbank.com/drugs/DB06199ApprovedInvestigationalAtrasentan is a novel, selective endothelin A receptor antagonist (SERA). … [L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist
Categories: Endothelin A Receptor AntagonistsTepotinib
go.drugbank.com/drugs/DB15133ApprovedInvestigational[A228058] MET is a desirable target in the treatment of certain solid tumors as it appears to play a critical role, both directly and indirectly, in the growth and proliferation of tumors in which it is … Tepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid tumors.
Human cord blood hematopoietic progenitor cell
go.drugbank.com/drugs/DB11054ApprovedUpon division and maturation at the bone marrow following intravenous administration to the patient, hematopoietic progenitor cells enter the systemic circulation to restore blood counts and function [ … Hemacord is marketed in the U.S. as an allogeneic cord blood hematopoietic progenitor cell therapy for intravenous use.